[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiangtan Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":94},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100648427","the-effect-of-autonomic-neuropathy-status-on-the-endpoint-events-in-diabetes-patients-with-coronary-heart-disease-and-sleep-apnea-100648427",false,"NCT07723222","The Effect of Autonomic Neuropathy Status on the Endpoint Events in Diabetes Patients With Coronary Heart Disease and Sleep Apnea.","The Effect of Autonomic Neuropathy Status on the Endpoint Events in Diabetes Patients With Coronary Heart Disease and Sleep Apnea: a Prospective Observational Cohort Study.","Inclusion Criteria:\n\n* The patient was diagnosed with coronary heart disease (coronary angiogram showed coronary artery stenosis ≥ 50%), diabetes (fasting blood glucose ≥ 7 mmol\u002FL, blood glucose ≥ 11.1 mmol\u002FL 2 hours after OGTT meal, HbA1c ≥ 6.5%, or random blood glucose ≥ 11.1 mmol\u002FL), and sleep apnea syndrome (≥ 5 apnea or hypoventilation events per hour during sleep, that is, AHI ≥ 5 times\u002Fhour, with associated symptoms or health risks. ）.\n\nExclusion Criteria:\n\n* Patients who have been implanted with permanent pacemakers; Patients with severe arrhythmia or myocardial infarction\u002Fstroke in the past 3 months; 48 hours prior to the experiment, the use of beta blockers, beta agonists ACE-I、ARB、 Patients with drugs such as adrenaline and dopamine; Pregnant women; Patients with serious diseases of important organs (such as heart, brain, kidney, liver, etc.); Patients with mental or physical disabilities; Unable to cooperate with patients undergoing examinations; Suspected or diagnosed patients with a history of alcohol or drug abuse; Patients with acute complications of diabetes, such as DKA, hypertonic coma, lactic acidosis, etc; Patients with thyroid dysfunction; Patients at risk of cardiac autonomic neuropathy (CAN), such as those with severe hypertension or proliferative retinopathy; Patients with electrolyte disorders such as hypokalemia.","ALL",{"count":18,"type":19},326,"ESTIMATED","3 Years","OBSERVATIONAL","Background: diabetes combined with cardiac autonomic neuropathy (CAN) can denervate the heart, which may prevent patients with sleep apnea syndrome from bradycardia in the early stage, and directly show an increased risk of tachyarrhythmia and sudden cardiac death. This means that many diabetes patients with sleep apnea syndrome who are at risk of sudden death may be ignored due to the lack of the typical signal of \"bradycardia\". A study showed 299 events among 165 participants, of which 132 participants (10%) had CAN and experienced 244 cardiovascular events, and 33 participants (25%) had CAN and experienced 55 cardiovascular events (hazard ratio \\[HR\\] 2.79, 95% CI 1.91). In this trial, the effect of autonomic neuropathy on the end point events of type 2 diabetes patients with coronary heart disease and sleep apnea was investigated.\n\nObjective: This study is a prospective, single-center, observational study to investigate the effect of autonomic neuropathy status on the endpoint events in patients with coronary heart disease, diabetes, and sleep apnea syndrome.\n\nMethods : Diagnosed coronary heart disease (coronary angiography showed coronary artery stenosis ≥ 50%), diabetes (fasting blood glucose ≥ 7 mmol\u002FL, blood glucose ≥ 11.1 mmol\u002FL 2 hours after OGTT meal, HbA1c ≥ 6.5%, or random blood glucose ≥ 11.1 mmol\u002FL), sleep apnea syndrome (≥ 5 apnea or hypoventilation events per hour during sleep (AHI ≥ 5 times\u002Fhour), and associated symptoms or health risks. ）The patient. The Ewing test was divided into two groups: the group without concomitant cardiac autonomic neuropathy and the group with cardiac autonomic neuropathy. The primary endpoint includes all-cause mortality events during follow-up, and the secondary endpoint includes the occurrence of cardiovascular events.\n\nThis study will explore the influence of autonomic neuropathy on the endpoint events of patients with diabetes, coronary heart disease and sleep apnea.\n\nKeywords: coronary heart disease, diabetes, sleep apnea syndrome, cardiovascular autonomic neuropathy, results",[24,25,26,27],"Coronary Heart Disease","Diabetes","Sleep Apnea Syndrome","Cardiovascular Autonomic Neuropathy (CAN)","NOT_YET_RECRUITING","2026-07-22",{"date":31,"type":32},"2026-07-23","ACTUAL",{"date":34,"type":19},"2026-08-01",{"date":36,"type":19},"2031-08-01",{"name":38,"class":39},"Xiangtan Central Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100556969","clinical-study-of-active-intervention-in-high-risk-hfpef-patients-100556969","NCT06532019","Clinical Study of Active Intervention in High-risk HFpEF Patients","Randomized Multicenter Clinical Trial in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) at Intermediate and High Risk of All-cause Death","Inclusion Criteria:\n\n* Discharged HFpEF patients with risk score \\> or equal 200.37.\n\nExclusion Criteria:\n\n* Patients with a life expectancy of less than 1-year due to malignancy.","18 Years",{"count":49,"type":19},924,"INTERVENTIONAL",[52],"NA","Based on inclusion and exclusion criteria, this experiment plans to include 924 Heart Failure with Preserved Ejection Fraction(HFpEF) patients with increased risk of all-cause death. The enrolled patients will divided into usual care group (n=462) and targeted intervention group (n=462) in a 1:1 ratio. The usual care patients will receive routine heart failure treatment. Patients in targeted intervention group, on top of routine therapy for heart failure, will receive further therapy targeting therapy to correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower N-terminal pro brain natriuretic peptide (NT-proBNP), C-reactive protein(CRP), New York Heart Association(NYHA )Classification, to add diuretics for patients with higher right ventricular diameters(RADs),multidiscipline intervention for patients complicating chronic obstructive pulmonary disease(COPD), and actively reperfusion for ischemic HFpEF patients. The incidence of all-cause death will be compared after 3 years follow-up.The primary endpoint is the occurrence of all-cause mortality events during the follow-up period.",[55],"Heart Failure With Preserved Ejection Fraction",[57],"all-cause mortality","2024-07-31",{"date":60,"type":32},"2024-08-01",{"date":60,"type":19},{"date":63,"type":19},"2028-08-01",{"name":38,"class":39},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":50,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100416790","phase-4-association-between-dapagliflozin-induced-improvement-and-anemia-in-heart-failure-patients-adidas-100416790","NCT04707261","Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","A Prospective, Randomized, Double-blind, Multicenter Study on the Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","ADIDAS","Inclusion Criteria:\n\n1. Male or female between the ages of 18 and 100 years.\n2. Elevated NT-proBNP or BNP levels on admission.\n3. Ejection fraction of 50% or less, and New York Heart Association (NYHA) class II, III, or IV symptoms.\n\nExclusion Criteria:\n\n1. Treatment with SGLT2-i during the past 3 months of admission,or previous intolerance of an SGLT2 inhibitor.\n2. Severe (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization.\n3. Pregnant or breast feeding female patients.","100 Years",{"count":75,"type":19},1990,[77],"PHASE4","The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.",[80,81],"Anemia","Heart Failure",[81,80,83],"Dapagliflozin","RECRUITING","2024-06-27",{"date":87,"type":32},"2024-07-01",{"date":89,"type":32},"2021-08-06",{"date":91,"type":19},"2026-01-01",{"name":38,"class":39},1,""]